Job description:
We are at the centre of the rapidly growing cell and gene therapy sector. We deliver life-changing therapies to patients, and so can you.
We are currently recruiting for a Scientist IV to join the Analytical Development and Technologies Group. The purpose of this role is to plan, execute and report experiments or analytical investigations to help the delivery of team goals and client work packages.
Your responsibilities in this role would be:
* Design, conduct and report development and qualification experiments for cell-based vector potency assays.
* Ensure a high standard of record keeping and documentation of experiments and investigations in order that information is clearly captured, disseminated, and reported.
* Present scientific data at internal meetings.
* Identify ideas and solutions for improvements to everyday tasks/ processes and potential new technologies.
* Training less experienced colleagues in relevant laboratory techniques, equipment, software, and methods.
Profile description:
We are looking for:
* Minimum BSc in a Biosciences or similar.
* Laboratory experience in tissue culture and flow cytometry is essential with immunological assays such as ELISA, ELISpot and luminescence based an advantage.
* Competency in data capture reporting and management systems.
* High level of familiarity with Microsoft Office.
* Knowledge of statistics and/ or AQBD/ DOE would be preferred.
* Knowledge in Virology and gene therapy products and experience working with viral vectors would be an advantage.
* Ability to work within a team and cross-departmentally and show initiative to seek solutions and problem-solve.
* Ability to work accurately in a busy and demanding environment.
* Credible and confident communicator (written & verbal) at all levels.
* Self-motivated with the ability to work proactively using own initiative.
About Us:
Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory expertise
What’s in it for you:
* Highly competitive total reward packages
* Wellbeing programmes
* Development opportunities
* Welcoming, friendly, supportive colleagues
* A diverse and inclusive working environment
* Our values are: Deliver Innovation, Be Inspiring and Have Integrity
* State of the art laboratory and manufacturing facilities
We want you to feel inspired every day. We’re future-focused and our business is growing rapidly. We succeed together through passion, commitment and teamwork, and so can you.
Collaborate. Contribute. Change lives
We offer:
Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies.
Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patient’s cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients’ cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy).
Oxford Biomedica collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
#J-18808-Ljbffr